Bristol Myers Gets FDA Accelerated Approval for Breyanzi

Bristol Myers Squibb got accelerated approval for Breyanzi in follicular lymphoma for patients who have received two or more prior lines of therapy.

• Generic name is lisocabtagene maraleucel
• Drug was originally developed by Juno Therapeutics, which was acquired by Celgene and later Bristol Myers Squibb in 2019
• Application was granted priority review and orphan drug designation
• NOTE: Bristol-Myers to Buy Celgene in $74 Billion Cancer-Drug Bet

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in New York at cbaker225@bloomberg.net

To contact the editors responsible for this story:
Zachary Fleming ...